About: Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks
Creator	Atzeni, Fabiola Corte, La Crisafulli, Salvatore Isgrò, Valentina Laura, · Trifirò, Gianluca
Source	Medline; PMC
abstract	The epidemic due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been spreading globally, raising increasing concerns. This public health emergency has triggered a race to find medications to improve the prognosis of this disease. There is currently great interest in drug repositioning to manage SARS-CoV-2 infection, that is, the evaluation of the potential benefits of a drug that has already been proven safe and effective in humans for other approved indications. As interleukin-6 (IL-6) acts as a key driver of the inflammation associated with coronavirus disease 2019 (COVID-19), IL-6 and IL-6 receptor (IL-6R) inhibition appear to be promising targets for the treatment of COVID-19 patients. It is important to critically analyze the available evidence concerning the use of the available anti-IL-6 (siltuximab) and anti-IL-6R (tocilizumab and sarilumab) agents in COVID-19 patients, in terms of both benefit and risk. In this review, the pathogenesis of the cytokine storm induced by COVID-19, the role of IL-6 in this cytokine storm, the rationale for the use of anti-IL-6 agents, and key information on potential benefits and safety monitoring of these biologicals in COVID-19 patients is discussed. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40259-020-00430-1) contains supplementary material, which is available to authorized users.
has issue date	2020-06-15(xsd:dateTime)
bibo:doi	10.1007/s40259-020-00430-1
bibo:pmid	32557214
has license	no-cc
sha1sum (hex)	54d0ca7de8fe84ef12474335f76c9184578be659
schema:url	https://doi.org/10.1007/s40259-020-00430-1
resource representing a document's title	Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks
has PubMed Central identifier	PMC7299248
has PubMed identifier	32557214
schema:publication	BioDrugs
resource representing a document's body	covid:54d0ca7de8fe84ef12474335f76c9184578be659#body_text
is schema:about of	named entity 'CURRENTLY' named entity 'EPIDEMIC' named entity 'DRUG REPOSITIONING' named entity 'DISEASE' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS' named entity 'EMERGENCY' named entity 'spreading globally' named entity 'prognosis' named entity 'infection' named entity 'epidemic' named entity 'critically ill' named entity 'COVID-19' named entity 'respiratory condition' named entity 'tocilizumab' named entity 'COVID-19' named entity 'CD4+ T lymphocytes' named entity 'observational studies' named entity 'ICU' named entity 'tocilizumab' named entity 'prognosis' named entity 'anti-IL-6' named entity 'ventilatory support' named entity 'respiratory rate' named entity 'tocilizumab' named entity 'EMA' named entity 'Inflammasomes' named entity 'monoclonal antibodies' named entity 'COVID' named entity 'siltuximab' named entity 'SARS-CoV' named entity 'neutropenia' named entity 'organ dysfunction' named entity 'CAR T-cell' named entity 'COVID' named entity 'clinical trials' named entity 'phase II' named entity 'COVID-19' named entity 'IL-6' named entity 'pathogenetic' named entity 'drug development' named entity 'CD4+' named entity 'noxious stimuli' named entity 'dyspnea' named entity 'rheumatoid arthritis' named entity 'COVID-19' named entity 'clinical evidence' named entity 'organ damage' named entity 'serum' named entity 'rheumatological' named entity 'IL-6' named entity 'cytopenias' named entity 'University of Messina' named entity 'viral replication' named entity 'Sanofi' named entity 'pharmaceutical companies' named entity 'toxicity' named entity 'pharmacoeconomics' named entity 'lung' named entity 'COVID-19' named entity 'hypersensitivity reactions' named entity 'anti-IL-6' named entity 'siltuximab' named entity 'receptor' named entity 'interleukin 6' named entity 'immunoglobulin' named entity 'cytokine' named entity 'RNA viruses' named entity 'receptor' named entity 'CAR T-cell' named entity 'randomized trials' named entity 'immune response' named entity 'cytokine' named entity 'RNA transcription' named entity 'protein' named entity 'macrophages' named entity 'antiviral'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software